NCT02231164
Clinical Trial Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02231164
Title LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Boehringer Ingelheim
Indications
lung adenocarcinoma
Therapies
Docetaxel
Nintedanib
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
1199.128.10032 Boehringer Ingelheim Investigational Site Chandler Arizona United States Details
1199.128.10041 Boehringer Ingelheim Investigational Site Fayetteville Arkansas United States Details
1199.128.10010 Boehringer Ingelheim Investigational Site Highland California United States Details
1199.128.10044 Boehringer Ingelheim Investigational Site Rancho Mirage California United States Details
1199.128.10080 Boehringer Ingelheim Investigational Site Paducah Kentucky United States Details
1199.128.10016 Boehringer Ingelheim Investigational Site Farmington New Mexico United States Details
1199.128.10013 Boehringer Ingelheim Investigational Site Minot North Dakota United States Details
1199.128.10077 Boehringer Ingelheim Investigational Site Blacksburg Virginia United States Details
1199.128.10011 Boehringer Ingelheim Investigational Site Kennewick Washington United States Details
1199.128.64006 Boehringer Ingelheim Investigational Site Batumi Georgia Details
1199.128.64001 Boehringer Ingelheim Investigational Site Tbilisi Georgia Details
1199.128.64002 Boehringer Ingelheim Investigational Site Tbilisi Georgia Details
1199.128.66004 Boehringer Ingelheim Investigational Site Bangkok Thailand Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field